Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for China SXT Pharmaceuticals's Net Margin % or its related term are showing as below:
FRA:2RY1'
s Net Margin % Range Over the Past 10 Years
Min: -545.26 Med: -175.26 Max: 24.27
Current: -545.26
FRA:2RY1's Net Margin % is ranked worse than 95.52% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs FRA:2RY1: -545.26
China SXT Pharmaceuticals (FRA:2RY1) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
China SXT Pharmaceuticals Net Margin % Related Terms
China SXT Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2RY1 vs CABR, BFRI, BIOE: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals (FRA:2RY1) has a Net Margin % of 32.13% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on China SXT Pharmaceuticals and its competitors. According to the industry distribution chart, China SXT Pharmaceuticals ranks #917 out of 960 companies in the Drug Manufacturers industry, placing it in the top 95.5%.
Is China SXT Pharmaceuticals' Net Margin % too high?
China SXT Pharmaceuticals' current Net Margin % is 32.13%. The Drug Manufacturers industry median Net Margin % is 5.56. China SXT Pharmaceuticals' value of 32.13% is 477.9% above this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #917 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Net Margin % compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #917 out of 960 companies for Net Margin %. This places China SXT Pharmaceuticals in the lower half of its industry. The industry median Net Margin % is 5.56. China SXT Pharmaceuticals' value of 32.13% is 477.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current Net Margin % of 32.13% is 477.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current Net Margin % is 32.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (FRA:2RY1) has a current Net Margin % of 32.13%. The stock's GF Value™ is €1.16, compared to a current price of €0.04 — trading 96.9% below its estimated fair value. The current Net Margin % is 32.13% and 477.9% above the Drug Manufacturers industry median of 5.56. China SXT Pharmaceuticals' overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY1), the current Net Margin % is 32.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (FRA:2RY1) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued.
The current stock price of €0.04 is trading 96.9% below its estimated GF Value™ of €1.16.
Key valuation signals for FRA:2RY1:
Net Margin %: 32.13%
GF Value™: €1.16 vs. price of €0.04 (96.9% below fair value)
Industry Position: 477.9% above the Drug Manufacturers median (#917 of 960)
No single metric tells the full story. See the FRA:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
40GF Score
Get the complete analysis for FRA:2RY1
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2RY1 has been successfully added to your 
